CNET tech sites: Price comparisons | Product reviews | Tech news | Downloads | Site map



CNET News lester News

▼ DJIA 7,857.78 -81.01 ▼ NASDAQ 1,199.72 -14.00 ▼ S&P 500 838.97 -8.94 ▼ CNETTECH 810.40 -0.52

Enter symbol Fast Quote, News & more...

Gol] - Asymbol Lookup

Market Update' My Portfolio' Brokerage Center' DO Center' Splits' Messages' Streaming Real Time Quotes


ProteoTech Receives Issuance of US Patent Pertaining to Diagnostic Applications of Particular Proteoglycans

10/2/02 6:03 AM Source: PR Newswire

KIRKLAND, Wash., Oct. 2 /PRNewswire/ -- ProteoTech ("Proteoglycan Technologies) Inc. was recently issued a US patent pertaining to the identification of a particular proteoglycan abnormality that can be detected in tissues, cells and biological fluids as a potential marker for a variety of human diseases, including Alzheimer's disease.

(Photo: http://www.newscom.com/cgi-bin/prnh/20020220/SFW009LOGO)

On August 13, 2002, ProteoTech was issued US Patent No. 6,432,636 entitled "Diagnostic Applications of Perlecan Domain I Splice Variants." The patent is assigned to University of Washington and licensed exclusively to ProteoTech. The patent invented by Grace A. Maresh (University of Washington) and Alan D. Snow, Ph.D. (now ProteoTech President & CSO) pertains to the identification of a particular heparan sulfate proteoglycan (known as "perlecan") which is altered in disease (producing variants known as "splice variants") that can be detected in tissues, cell and biological fluids (such as cerebrospinal fluid or blood). In Alzheimer's disease, four different variant abnormalities have been identified in brain



tissue (i.e. splice variants), one of which was present in brains of all (i.e. 10 out of 10 patients) with Alzheimer's. Antibodies made against these proteoglycan abnormalities localized these variants to the brain pathological hallmarks (i.e. amyloid plaques and neurofibrillary tangles) observed in all patients with Alzheimer's disease.

This patent covers the composition of the different proteoglycan variants, the use of various techniques to identify these particular proteoglycan abnormalities in tissues, cells and biological fluids, and diagnostic applications for different human diseases. Adding this US Patent to ProteoTech's intellectual property estate is believed to place ProteoTech in a unique proprietary position in the field of proteoglycan research, particularly as it applies to Alzheimer's and other amyloid disorders.

ProteoTech is a private drug discovery and research development Company focused on therapeutics and diagnostics for specific human diseases, which involve "proteoglycans" in the disease pathogenesis. Proteoglycans are synthesized by virtually all cells of the body and play significant roles in the pathogenesis of a number of human diseases. ProteoTech is in pre-clinical development of therapeutics for Alzheimer's disease, Parkinson's disease, prion diseases, type 2 diabetes, and systemic amyloidosis.

For licensing opportunities related to this press release, please contact: Alan D. Snow, President & CSO at snow@proteotech.com,

MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X08837656

SOURCE ProteoTech inc.

Copyright 2000, PR Newswire

'Quote Snapshot

 DJI
 7,857.00
 -81.70

 COMPX
 1,200.13
 -13.59

 INX
 838.66
 -9.25

Æ iessages

Enter symbol:



Quotes delayed 20+ minutes